RaQualia Pharma (TSE:4579) Inventory Turnover: 1.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円458.00
GF Value 円310.31
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Inventory Turnover?

RaQualia Pharma TSE:4579 -3.78% 59 Inventory Turnover is 1.13 as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 59/100 and a GF Value™ of 円310.31 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. RaQualia Pharma's Cost of Goods Sold for the three months ended in Mar. 2026 was 円181 Mil. RaQualia Pharma's Average Total Inventories for the quarter that ended in Mar. 2026 was 円161 Mil. RaQualia Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.13.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. RaQualia Pharma's Days Inventory for the three months ended in Mar. 2026 was 81.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. RaQualia Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.20.

RaQualia Pharma  (TSE:4579) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

RaQualia Pharma's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=160.5795/180.9*365 / 4
=81.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

RaQualia Pharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=160.5795 / 801.993
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

RaQualia Pharma Inventory Turnover Related Terms

RaQualia Pharma Inventory Turnover Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Inventory Turnover Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.53 24.32 3.13 3.96 4.35

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 0.97 0.00 0.00 1.13
TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Inventory Turnover Calculation

RaQualia Pharma's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=711.953 / ((167.722 + 159.766) / 2 )
=711.953 / 163.744
=4.35

RaQualia Pharma's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=180.9 / ((159.766 + 161.393) / 2 )
=180.9 / 160.5795
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 1.13 mean?
RaQualia Pharma (TSE:4579) has a Inventory Turnover of 1.13 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Inventory Turnover too high?
RaQualia Pharma's current Inventory Turnover is 1.13. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Inventory Turnover compare to VRTX and REGN?
RaQualia Pharma's Inventory Turnover of 1.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Inventory Turnover is 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.31, compared to a current price of 円458.00 — trading 47.6% above its estimated fair value. The current Inventory Turnover is 1.13. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Inventory Turnover is 1.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円458.00 is trading 47.6% above its estimated GF Value™ of 円310.31. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Inventory Turnover: 1.13
  • GF Value™: 円310.31 vs. price of 円458.00 (47.6% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円458.00
Price
円310.31
GF Value